POLA-R-CHP in the First-line Treatment of Transformed DLBCL

This study tests a first-line chemotherapy combination called POLA-R-CHP (which includes a targeted antibody-drug conjugate called polatuzumab vedotin along with rituximab and chemotherapy) for people with transformed diffuse large B-cell lymphoma (DLBCL) — a type of aggressive lymphoma that has changed from a slower-growing lymphoma. **You may be eligible if...** - You are between 18 and 80 years old - You have been confirmed by biopsy to have transformed DLBCL - You are in good physical condition (ECOG 0–2) - Your blood counts, liver, kidney, and heart function are adequate **You may NOT be eligible if...** - You are allergic to monoclonal antibodies - You have had a prior organ transplant - You have received cytotoxic chemotherapy or anti-CD20 antibody therapy in the past 5 years - You have significant heart or lung disease - You have active or uncontrolled serious infection - You have active hepatitis B, active hepatitis C, HIV, or syphilis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.